An Unhappy New Year for Asthma Patients
![](https://allianceforpatientaccess.org/wp-content/uploads/2023/11/AdobeStock_202973845-1024x683.jpeg)
Health economists have put a damper on asthma patients’ hopes for better disease management in 2022.
ICER’s Asthma Report Comes up Short
![](https://allianceforpatientaccess.org/wp-content/uploads/2023/11/AdobeStock_219708836-1024x683.jpeg)
It’s plagued by incomplete analysis and missing data, yet the Institute for Clinical and Economic Review’s draft evidence report on severe asthma medicine still manages to deliver a familiar refrain. All five of the drugs reviewed, ICER reports, are not cost-effective.
Can ICER Put a Price on Asthma Control?
![](https://allianceforpatientaccess.org/wp-content/uploads/2023/11/asthma-control.png)
The Institute for Clinical and Economic Review says new medicine for uncontrolled asthma isn’t worth its cost. But its analysis omits key details. View the Graphic. View Social Graphics.